SME files patent for ‘game-changing’ lateral flow test technology 

Nano Biosols, an SME based at Liverpool Science Park, UK, has filed a patent for novel technology it has developed to enhance the sensitivity of lateral flow tests, enabling use across a much broader range of diseases. 

Lateral flow tests have been routinely used during the pandemic to detect infection. However, although lateral flow tests are a relatively cheap, user-friendly, and effective testing method, they are generally not as sensitive as a PCR test for detecting active infection. Nano Biosols’ novel gold nanoparticle technology can reportedly improve the sensitivity and readability of lateral flow tests in cases where detection lines are only faintly displayed. 

Through the Infection Innovation Consortium (iiCON)’s Merseyside SME support programme, Nano Biosols worked with iiCON and its partners at Liverpool School of Tropical Medicine (LSTM) to undertake initial testing and evaluation of its novel technology. The diagnostics team at LSTM was able to evaluate lateral flow test performance with and without the addition of the Nano Biosols reagent and showed improved detection limits and readability of tests. 

Image credit: Annie Spratt

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free